Introduction
From its approval by the FDA in 1997 for the treatment of refractory partial epilepsy, the vagus nerve stimulation (VNS) therapy system has been implanted in over 100,000 patients worldwide. 1 Numerous reports have established VNS therapy as a safe and effective treatment option for children and adults who have refractory epilepsy. [1] [2] [3] [4] [5] [6] The cost effectiveness of VNS therapy has also been assessed and established in the developing world, 7, 8 however there are very little reports on its use in developing countries, 9 and none that address cost related issues. In this report,
we describe the experience with VNS therapy in children with refractory epilepsy from the two major university hospitals in Jordan, and perform an analysis of direct hospital costs and cost utility.
Materials and methods
This is a retrospective review of all children who underwent VNS implantation at King Abdullah University Hospital, and Jordan University Hospital. King Abdullah University Hospital is an urban, JCIA a accredited, tertiary referral hospital in the north of Jordan, and Jordan University Hospital is a JCIA accredited tertiary referral hospital in the capital Amman. Detailed clinical evaluation, brain magnetic resonance imaging results, and electroencephalography results were collected for all patients. Parents were instructed to keep seizure diaries for at least two months prior to implantation of the device, and to continue with the diaries after implantation.
Data regarding seizure frequency, seizure severity, and complications of VNS therapy were collected every visit, as was data regarding the child's behavior, alertness, and interaction. Seizure severity was assessed by duration of seizures, intensity of convulsive phenomena, loss of posture or injury during seizures, frequency of status epilepticus episodes, duration of postictal phenomena, and speed of recovery. The McHugh VNS specific outcome scale was utilized for assessment of seizure frequency and severity after implantation. 10 Data regarding frequency of emergency room visits, ward admissions, and intensive care unit admissions pre and post VNS implantation was collected retrospectively from patients' medical records and from caregivers.
QALY was calculated as the product of age specific life expectancy and average utility scores. Utility scores utilized were determined using data from Forbes et al. 11 A utility score of 0.848 was assigned to the months where patients' seizure frequency was less than once a month, and a utility score of 0.681 was assigned to the months where patients' seizure frequency was more than once a month. A utility value of 0.285 was assigned to patients with more than 50% reduction in seizure frequency. QALY was calculated for the 6 months prior to VNS implantation and the total post VNS period. Cost per QALY was calculated by dividing net cost (total cost minus costs averted) by the number of QALYs gained over a six year period (assuming battery life of 6 years).
The study was approved by the ethics committee.
Statistics
Statistical summaries were used to describe dependent and predictor variables. An ordinal logistic regression was utilized when dependent variables were counts, and was fitted for comparisons between the pre and post VNS periods regarding number of seizures and ER visits. ANOVA and correlations were utilized when the dependent variables were continuous; ANOVA was fitted for evaluating the effect of gender and seizure type on seizure frequency reduction, and correlations with confidence intervals of 95% were calculated to evaluate the effect of age of epilepsy onset, age at VNS surgery, and duration of epilepsy on seizure frequency reduction. When multiple comparisons were needed (e.g. effect of different seizure types on seizure frequency reduction) Tukey HD method was used. JMP software was utilized for analysis with a = 0.05. patient was excluded from this review because of accidental death shortly after implantation, of causes unrelated to his underlying condition or the device. Mean age at implantation was 9.4 years (2-19). Mean duration of epilepsy prior to implantation was 6.5 years. The most common seizure type was generalized tonic clonic seizures, followed by focal seizures, and atonic seizures, (14, 13, and nine patients respectively). Eleven patients had mixed seizures. The most common epilepsy syndrome was Lennox Gastaut syndrome (eight patients), followed by focal epilepsy of unknown etiology (seven patients), and symptomatic focal epilepsy (six patients), Table 2 . Dravet syndrome was diagnosed in two patients. Sixteen patients had mental retardation. All patients had failed to respond to at least four antiepileptic medications, and all were on multiple antiepileptic medications at the time of implantation.
Results

Patient characteristics
Device implantation
Device implantation at King Abdullah University Hospital was performed by otolaryngology service by the same team (23 patients), while the remaining five devices at Jordan University Hospital were implanted by neurosurgery service. Review of operative notes showed mean operative time for VNS implantation was 80 min. No significant intraoperative complications were reported, namely no significant blood loss or cardiac adverse events.
The VNS device was switched on two weeks after surgery for all patients. Initial settings were: output current 0.25 mA, frequency 30 Hz, pulse width of 250 ms, on-time 30 s, and off-time 5 min.
Thereafter output current was increased every two to four weeks by 0.25 mA to a target output of 1.75-2.25 mA according the patient response. Duty cycle changes were performed according to seizure outcome and patient tolerance.
Seizure outcome
Follow up data was available for all patients. All patients were followed for a minimum of three years, 22 patients had follow up of five or more years. After 3 years of VNS therapy, seizure outcome was rated as McHugh's class I (80-100% reduction in seizure frequency) in seven patients, class II (50-79% reduction in seizure frequency) in nine patients, class III (<50% reduction in seizure frequency) in four patients, and class V (no improvement) in seven patients. None of the patients experienced significant benefit from activating the device by the magnet (class IV). All patients in class I and II showed significant reduction in ictal and postictal activity (McHugh's class IA and IIA).
Most patients with 50% or more reduction in seizure frequency showed improvement within nine months of device implantation, Fig. 1 . This improvement stabilized by 18-24 months. Both patients with Dravet syndrome showed significant reduction in seizure frequency, abolished drop attacks, reduction in seizure severity, and improved alertness and communication. However, there was no statistically significant effect of epilepsy syndrome on seizure frequency reduction, Fig. 2 .
The overall mean number of seizures per month showed a significant reduction from 85.7 seizures/month pre VNS to 16.1 seizures/month post VNS, (p = 0.0022). Comparing the mean reduction in number of seizures between the three major seizure types (generalized, focal, and atonic), there was a mean reduction of 25.9 seizures/month for generalized tonic clonic seizures, 74.2 seizures/month for focal seizures, and 90.2 seizures/month for atonic seizures. Utilizing Tukey method for multiple comparisons, there was a significant difference in reduction means between atonic and generalized tonic clonic seizures, with a difference in means of 64.3 seizures/month, (p = 0.0377).
QALY gained after VNS implantation
Data regarding life expectancy in Jordan was obtained from the WHO Global Health Observatory Data Repository (http://apps.-who.int/gho/data). Table 3 summarizes the results of QALY analysis. For children aged 1-9 years the average gain in QALY was 3.78 years over lifetime, and for adolescents aged 10-19 years the average gain in QALY was 1 year over lifetime.
Direct hospital costs and cost utility analysis
Direct hospital costs prior to VNS implantation were calculated in relation to ER visits and ICU admissions. There was a significant reduction in the mean number of ER visits per month post VNS relative to pre VNS (0.73 vs 3.0 respectively, p = 0.042). In 5 patients who had frequent status epilepticus events, the total number of intensive care unit admissions dropped from 13 admissions in the 3 years prior to implantation to none in the last 3 years after implantation.
In Jordan, ER visits to ministry of health hospitals cost an average of 10 US dollars, including cost of labs and possible administration of IV diazepam, or the cost of attending to a head laceration in cases of atonic seizures. In the two university hospitals where the patients were recruited for this study an ER visit costs around 20 US dollars. For the patients who showed a significant drop in ER visits after implantation, the calculated total direct hospital costs related to ER visits in the six months prior to implantation was around 7200 US dollars. Estimating that without implantation these patients would continue to have the same frequency of ER visits, cost savings for these patients after implantation was calculated assuming a battery life of a minimum 6 years. Using this calculation, total savings related to reduction in ER visits amounted to around 86,400 US dollars. Regarding ICU admission costs, the cost of ICU admission per day was calculated to be an average of 500 USD. From medical records total number of days in ICU for all patients was 37 days over the 3 years prior to VNS implantation, and none after implantation. Using this calculation, costs averted from decreased ICU admissions was calculated to be 18,500 USD. Total costs savings from decreased ER visits and ICU admissions was 104,900 USD. Divided by the total number of patients, there was a savings of 3885 USD per patient. VNS implantation therapy in Jordan costs an average of 12,000 USD per patient.
To calculate cost per QALY gained, patients with more than 50% reduction in seizure frequency were assigned a utility value of 0.285 (time trade off experiments by Forbes et al.) . Applying this to the 15 patients with more than 50% reduction in seizure frequency, and a battery life of 6 years (none of our patients with more than 5 years follow up required change in battery), and using the total cost savings of 104,900 USD, cost per quality adjusted life years was 4089 USD per successful device.
Complications and adverse events
One patient had intraoperative oozing. Two patients had postoperative infection within the first week of implantation and were treated with intravenous antibiotics. One of these patients eventually required removal of the device because of recurrent methicillin resistant staph aureus infection. One patient had wound dehiscence one week after surgery that was surgically treated, and one patient required repositioning of the device due to prominence of the device and neck leads. One patient required reimplantation of the device due to electrode failure.
The most common device related adverse events were cough, shortness of breath, and weight loss, Table 4 . Weight loss related to decrease oral intake was reported in seven patients, and was significant in five. Three of these patients had normal intelligence and reported decreased appetite. Analgesics did not improve oral intake in the noncommunicative patients, and in one patient decreasing the stimulation intensity did help. Two patients with no benefit from the device and significant weight loss had the device either removed or turned off with subsequent increase in oral intake and weight.
Discussion
At the two major university hospitals in Jordan, between 2007 and 2011, 28 patients underwent VNS therapy implantation for refractory epilepsy. Retrospective review of these patients showed that in 59%, there was a reduction in seizure frequency of 50% or more after a mean follow up of three years, with a statistically significant reduction in total number of seizures per month. These results are similar to those in previous reports on VNS therapy in children with epilepsy. 1, [16] [17] [18] In this report, there was no significant correlation between epilepsy syndrome and seizure frequency reduction, however, atonic seizures were more likely to respond to VNS therapy when compared to generalized tonic clonic seizures. Predictors of seizure freedom with VNS therapy have not been consistent and at times conflicting, [19] [20] [21] [22] however several reports have shown a favorable response of drop attacks to VNS therapy. 18, 23, 24 Other reports have highlighted the particular efficacy of VNS implantation in specific epilepsy syndromes, particularly epileptic encephalopathies. 16, 18, 25 Our observation of progressive improvement in seizure control in the first 24 months after implantation with subsequent plateau of effect is similar to previous observations. 2, 26, 27 This is one of the first reports on QALY gain after VNS implantation. 28 There was a QALY gain of about 378 years for 100 children and 100 years for 100 adolescents. This is significantly more than QALY gain reported by Messori et al. for patients treated with lamotrigine 29 , but significantly less than the QALY gain reported by Helmers et al. 28 As reported by Helmers et al.,
their estimate of QALY gain is probably an overestimation due to the fact that they utilized hospitalizations and ER visits as proxies for seizure occurrences. This was a small sample of patients; however data regarding seizure frequency and severity was directly available for all patients for utilization in QALY analysis. In this group, children gained more QALYs than adolescents, related to the fact that most patients with less than one seizure per month post implantation were within this age group, and a higher life expectancy for this age group. Limiting our QALY analysis is the fact that utility scores developed by Forbes et al. were used 11 ; these utility scores were deduced for adults with refractory epilepsy in a developed country. Indeed, in any case, attempting to deduce utility values for children with refractory epilepsy, who have cognitive challenges, using currently available instruments (EQ-5D, time trade off, etc.. . .) would be compromised given that parents must act as proxies for completion of these exercises. It has been shown that VNS therapy is cost effective in developed countries. 7, 8 Helmers et al. showed that cost savings started to outweigh the average total costs of the VNS device and implantation procedure after 1 year for adolescents and 1.5 years for children. 28 In this group of patients, direct hospital costs savings was related to reduction in seizure severity with significant reduction in ER visits and ICU admissions. Complications such as hospitalization for infections were not included in our analysis; in the report by Forbes et al., up to a 10% complication rate did not lead to a significant increase in cost per QALY.
11
Despite not reaching the cost savings seen in developed countries, the financial burden of the device was reduced by about 30% per patient, and cost per QALY for successful devices was around 4000 USD per successful device. Factors leading to limitation in direct cost savings in our group of patients include the low cost of medical care, the fact that only a margin of the care provided in developed countries is available, and VNS implantation costing approximately the same as in developed countries. Although cost per QALY was lower than that reported by Helmers et al., it is difficult to interpret this value as the optimal threshold for cost effectiveness in Jordan or similar developing countries has not been previously determined. This low cost per QALY however is consistent with the sensitivity analysis performed by Forbes et al. that showed lower cost per QALY if the battery life was increased to 6 years, or if response rate was more than 1 in 6 patients; in this report almost 1 in 2 patients showed a 50% improvement in seizure frequency.
Epilepsy surgery, with its cost and infrastructural requirements, continues to be an unattainable option for most patients with refractory epilepsy in Jordan, and most of the developing world. 12, 13 There have been several reports demonstrating successful models for epilepsy surgery in developing countries utilizing technology and expertise reasonably available in the developing world. [13] [14] [15] However, these reports have understandably been on adults, for highly selected patients with straightforward intractable temporal lobe epilepsy. Efforts at establishing successful epilepsy surgery programs in most developing countries continue to be hampered by limited sustained resources and at times by factors such as poor adherence to capability by medical personnel.
It is easy to appreciate the attractiveness of the VNS therapy system in such a setting; it is a relatively uncomplicated surgical procedure that is not technologically demanding. In the absence of epilepsy surgery as a viable option, the preoperative investigations are aimed at confirming the presence of refractory epilepsy which can be achieved by available noninvasive procedures.
In developing countries like Jordan no policies exist for financial coverage of VNS implantation, there is continued skepticism regarding the cost of the device, and allocation of limited resources is necessary. This analysis shows it might be reasonable to propose to initially target patients with refractory epilepsy who have frequent utilization of health care resources (e.g. frequent status epilepticus, frequent admissions, and frequent ER visits for drop attacks and associated injuries), where the device shows the most cost savings. Although this might sound like treatment rationing, in reality it is a means to provide more patients with refractory epilepsy with a much needed therapy.
The interpretation of our observations was naturally limited by the retrospective nature of the analysis, small number of patients, and selection bias of children with refractory epilepsy regarding implantation. QALY analysis and cost effectiveness were based on utility scores previously deduced on a different population of patients. Studies assessing appropriate means for arriving at utility values for children with refractory epilepsy are needed, as are studies assessing incremental cost effectiveness ratios with control populations.
In conclusion, VNS implantation in Jordan was found to be feasible, effective and well tolerated. Cost utility analysis was encouraging, with improving cost effectiveness and cost utility expected if targeted patient selection is implemented.
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